Form 4: Director Shalini Sharp Exercises NBIX Stock Units

Neurocrine Biosciences Director Shalini Sharp acquired 1,659 shares of common stock through the vesting of restricted stock units.

Summary

• Director Shalini Sharp acquired 1,659 shares of Neurocrine Biosciences (NBIX) common stock on May 21, 2026.
• The acquisition resulted from the vesting of restricted stock units (RSUs) granted on May 21, 2025.
• The transaction was executed at a price of $0 per share as part of a standard equity compensation vesting schedule.
• Following this transaction, the reporting person holds a total of 4,088 shares of common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as it represents the standard vesting of director compensation rather than a discretionary market trade.

Positives

• The transaction reflects the fulfillment of equity-based compensation, aligning director interests with long-term shareholder value.

Negatives

• None.

Risks

• None.

Future Outlook

Not applicable as this is a routine disclosure of equity compensation vesting.

Industry Context

StockSavvy.ai notes that routine RSU vesting for board members is a standard corporate governance practice in the biotechnology sector, intended to maintain director retention and alignment with company performance.

Comparison to Industry Standards

• The transaction follows standard industry practices for equity-based compensation for non-employee directors in the biopharmaceutical industry.

Stakeholder Impact

• Minimal impact on shareholders as this is a routine equity compensation event.

Next Steps

• None.

Key Dates

Keywords

NBIX, Neurocrine Biosciences, Form 4, Insider Trading, Equity Compensation, Director Ownership